Amifampridine Phosphate

磷酸阿米吡啶

Report date: 2026/04/13 20:02:18
NME

Base Information

Drug NameAmifampridine Phosphate
Drug Alias Name二氨吡啶AmifampridinaAmifampridinum磷酸阿米吡呖3,4-DAP phosphate +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium channel blockersVoltage-gated potassium channel blockers
TargetsPotassium channelVoltage-gated potassium channel
Therapy Area/IndicationsFatigueMyasthenic Syndromes, CongenitalSpinal Muscular Atrophies of Childhood +[8] 
Global Approved IndicationsLambert-Eaton Myasthenic Syndrome
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2009/12/23
Country/TerritoryUnited StatesPolandSerbia +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBiomarin Pharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesDydo Pharma IncCatalyst Pharmaceuticals IncSerb SA
Inactive CompaniesJacobus PharmaceuticalAarhus UniversityNational Center For Research Resources
Active IndicationsMuscular Atrophy, SpinalLambert-Eaton Myasthenic Syndrome
Inactive IndicationsFatigueMyasthenic Syndromes, CongenitalSpinal Muscular Atrophies of Childhood +[6] 

Other Information

ATC CodeN07XX05
Related LinksDrugBankKEGG